Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

153 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture. See the species affected, top reactions, and outcomes below.

153
adverse-event reports
7.2%
death-coded share
Dog
most-reported species
34
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
153
Total Reports
11
Deaths Reported
7.2%
Death Rate

Active Ingredients

Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

Administration Routes

NasalUnknownSubcutaneousOralOtherParenteral

Species Affected

Dog 153

Most Affected Breeds

Retriever - Labrador 17
Terrier - Yorkshire 12
Retriever - Golden 9
Chihuahua 7
Shih Tzu 6
Pit Bull 5
Boxer (German Boxer) 5
Bulldog - French 5
Siberian Husky 5
Crossbred Canine/dog 4

Most Reported Reactions

Vomiting 34
Lethargy (see also Central nervous system depression in 'Neurological') 24
Lack of efficacy - NOS 20
Diarrhoea 20
Cough 19
Other abnormal test result NOS 17
Anaphylaxis 13
Death 10
Pale mucous membrane 9
Lack of efficacy (virus NOS) 9
Lethargy (see also Central nervous system depression in Neurological) 9
Anorexia 8

Outcome Breakdown

Outcome Unknown
73 (47.7%)
Recovered/Normal
37 (24.2%)
Ongoing
32 (20.9%)
Died
11 (7.2%)

Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture Adverse Event Insights

153 reports name Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture; 11 recorded a death outcome (7.2% of reported events, not a population-level mortality rate). Active ingredient: Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture. Administration routes: Nasal, Unknown, Subcutaneous, Oral.

By species: Dog (153 reports). By breed: Retriever - Labrador (17), Terrier - Yorkshire (12), Retriever - Golden (9).

Leading clinical signs: Vomiting (34), Lethargy (see also Central nervous system depression in 'Neurological') (24), Lack of efficacy - NOS (20), Diarrhoea (20). Outcome, 153 coded reports: Outcome Unknown leads at 47.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.